« Back
Home /
Anti-Human DRAK2 (CT) - 0.1 mg

Anti-Human DRAK2 (CT) - 0.1 mg

Item no.	LEIN-D258-0.1mg
Manufacturer	Leinco Technologies
Amount	0.1 mg
Quantity options	0.1 mg 20 ug
Category	Antibodies Immunohistochemistry Western Blot Primary Antibodies
Type	Antibody Primary
Applications	WB, IHC
Specific against	Human (Homo sapiens)
Host	Rabbit
Citations	1. Sanjo, H. et al. (1998) J Biol Chem 273:29066-71.
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Shipping Condition	Room temperature
Available
Manufacturer - Applications	IHC FFPE, WB
Manufacturer - Category	Primary Monoclonal Antibodies>Apoptosis & Cell Biology
Manufacturer - Targets	DRAK2
Country of Origin	USA
Shipping Temperature	Next Day Ambient
Storage Conditions	This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Product Description	Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases).1 DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.1
Background	Apoptosis is mediated by death domain containing adapter molecules and a caspase family of proteases. Certain serine/threonine protein kinases, such as ASK-1 and RIP, are mediators of apoptosis. Two novel serine/threonine kinases that induce apoptosis were recently identified and designated DRAK1 and DRAK2 (for DAP kinase-related apoptosis-inducing protein kinases).¹ DRAKs contain an N-terminal kinase domain and a C-terminal regulation domain. Overexpression of DRAK2 induces apoptosis. DRAKs have high sequence homology to DAP and ZIP kinases, and they represent a novel family of serine/threonine kinases, which mediates apoptosis through their catalytic activities. DRAK2 is located in nucleus and the messenger RNA was ubiquitously expressed in human tissues.¹
PubMed	DRAK2
Manufacturer - Specificity	Anti-Human DRAK2 recognizes an epitope near the C-terminus of Human DRAK2. This polyclonal antibody was purified using affinity chromatography.
RRID	AB_2829912
Concentration	0.5 mg/ml
Formulation	This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen	PN:D282
Additional Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords	DRAK2 Antibody, DRAK2, DRAK2, DAP kinase-related apoptosis-inducing protein kinase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

LEIN-D258-0.1mg-safety-datasheet.pdf